0001104659-21-147884.txt : 20211209 0001104659-21-147884.hdr.sgml : 20211209 20211209080154 ACCESSION NUMBER: 0001104659-21-147884 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211208 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211209 DATE AS OF CHANGE: 20211209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marker Therapeutics, Inc. CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37939 FILM NUMBER: 211480312 BUSINESS ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: (713) 400-6400 MAIL ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC. DATE OF NAME CHANGE: 20170629 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC DATE OF NAME CHANGE: 20070628 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 8-K 1 tm2134930d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

December 8, 2021

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37939	45-4497941
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3200 Southwest Freeway

Suite 2500

Houston, Texas

77027

(Address of principal executive offices)

(Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective December 8, 2021, the Board of Directors (the “Board”) of Marker Therapeutics, Inc. (the “Company”) appointed Katharine Knobil, M.D. as a member of the Board, to serve until the Company’s 2022 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier resignation or removal.

Pursuant to the Company’s Director Compensation Program, as may be amended from time to time (the “Program”), Dr. Knobil will receive annual cash compensation in the amount of $40,000 for her Board service. Such amounts will be paid quarterly and pro-rated for 2021. The Company will also reimburse Dr. Knobil for travel expenses incurred in connection with her attendance at Board meetings. On December 8, 2021, Dr. Knobil was granted an initial one-time option to purchase 125,000 shares of the Company’s common stock (the “Option”). Subject to Dr. Knobil’s continued service on the Board, the Option will vest in equal monthly amounts over a three-year period. In accordance with the Program, Dr. Knobil will also be eligible to receive an annual option award to purchase shares of the Company’s common stock, subject to Dr. Knobil’s continued service on the Board.

As of the time of the filing of this Current Report on Form 8-K, the Board has not determined the committees, if any, to which Dr. Knobil will be appointed. If Dr. Knobil is appointed to serve on a committee of the Board, she will be entitled to additional cash compensation under the Program in connection with such service.

There were no arrangements or understandings between Dr. Knobil and any other persons pursuant to which she was selected as a director, and there are no related person transactions within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission between Dr. Knobil and the Company required to be disclosed herein.

Item 7.01

Regulation FD Disclosure.

On December 9, 2021, the Company issued a press release announcing the appointment of Dr. Knobil to the Board. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated December 9, 2021
104	Inline XBRL for the cover page of this Current Report on Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Marker Therapeutics, Inc.

Dated: December 9, 2021				By:		/s/ Anthony Kim
						Anthony Kim
						Chief Financial Officer

EX-99.1 2 tm2134930d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Houston, TX –December 9, 2021– Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Katharine Knobil, M.D., to the Company’s Board of Directors.

“We are excited to announce the appointment of Dr. Knobil to the Board of Directors,” said Peter L. Hoang, President & CEO of Marker. “Dr. Knobil’s extensive leadership experience in clinical development of new therapies, including 20 years of leadership at GlaxoSmithKline plc, will serve Marker well as the Company advances its novel cell therapies in the clinic. We look forward to Dr. Knobil’s valuable counsel and expertise.”

Dr. Knobil currently serves as Chief Medical Officer at Agilent Technologies, Inc. Prior to Agilent, she served as Chief Medical Officer and Head of Research and Development at Kaleido Biosciences, Inc. Previously, Dr. Knobil served in various leadership positions during a 20-year career at GlaxoSmithKline plc, before becoming Chief Medical Officer. Dr. Knobil received a B.A. in Biological Sciences from Cornell University and an M.D. from the University of Texas Southwestern. She currently serves on the Board of Directors of Arena Pharmaceuticals Inc.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Contacts

Investors

Solebury Trout

Xuan Yang

(646) 378-2975

xyang@soleburytrout.com

Media

Solebury Trout

Amy Bonanno

(914) 450-0349

abonanno@soleburytrout.com

EX-101.SCH 3 mrkr-20211208.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mrkr-20211208_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mrkr-20211208_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2134930d1_ex99-1img001.jpg GRAPHIC begin 644 tm2134930d1_ex99-1img001.jpg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end XML 7 tm2134930d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001094038 2021-12-08 2021-12-08 iso4217:USD shares iso4217:USD shares 0001094038 false 8-K 2021-12-08 MARKER THERAPEUTICS, INC. DE 001-37939 45-4497941 3200 Southwest Freeway Suite 2500 Houston TX 77027 713 400-6400 false false false false Common Stock, par value $0.001 per share MRKR NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 08, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 08, 2021
Entity File Number	001-37939
Entity Registrant Name	MARKER THERAPEUTICS, INC.
Entity Central Index Key	0001094038
Entity Tax Identification Number	45-4497941
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3200 Southwest Freeway
Entity Address, Address Line Two	Suite 2500
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77027
City Area Code	713
Local Phone Number	400-6400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MRKR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://tapimmune.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2134930d1_8k.htm mrkr-20211208.xsd mrkr-20211208_lab.xml mrkr-20211208_pre.xml tm2134930d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2134930d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2134930d1_8k.htm" ] }, "labelLink": { "local": [ "mrkr-20211208_lab.xml" ] }, "presentationLink": { "local": [ "mrkr-20211208_pre.xml" ] }, "schema": { "local": [ "mrkr-20211208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mrkr", "nsuri": "http://tapimmune.com/20211208", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm2134930d1_8k.htm", "contextRef": "From2021-12-08to2021-12-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://tapimmune.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "tm2134930d1_8k.htm", "contextRef": "From2021-12-08to2021-12-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://tapimmune.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-147884-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-147884-xbrl.zip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end